Small molecules activating RET for the treatment of Parkinson's disease

Projektinformationen

GDNF mimetics

ID Finanzhilfevereinbarung: 612275

Abgeschlossenes Projekt

Startdatum 1 November 2013

Enddatum 31 Oktober 2017

Finanziert unter

• Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)

Gesamtkosten € 870 268,00

EU-Beitrag € 870 268,00

Koordiniert durch

HELSINGIN YLIOPISTO
Finland

Ziel

Parkinson’s disease (PD) is caused by degeneration and progressive loss of dopaminergic (DA) neurons of the substantia nigra. In Western countries more than 6 million people live with PD. Currently no cure for this disease is available, existing therapeutic strategies alleviate PD symptoms but do not influence its cause or in other words do not prevent or slow down degeneration of DA neurons. Glial cell line-derived neurotrophic factor (GDNF) is one of the few molecules able to protect and repair DA neurons in animal models of PD. GDNF protein and the related factor neurturin were tested in five clinical trials, but the results have been inconclusive. The pharmacokinetic properties of these proteins complicate their therapeutic development. They do not pass blood-brain-barrier (BBB). Moreover, these factors diffuse poorly from the site of injection.
The purpose of current proposal is to combine expertises of the academic and industrial partner in the fields of computational/medicinal chemistry (industrial participant), molecular/behavioural neuroscience and neuropharmacology (academic participant) to develop small molecules passing BBB and efficiently protecting and repairing dopaminergic neurons in vivo. We have developed an initial set of hits that activate GDNF receptors that at 1-10 uM concentration protect and repair DA neurons in vitro. We plan to optimize existing molecules and develop new ones to achieve an active concentration in the range 1-10nM using rational drug design approaches and cell-based screening methods developed by us.
Successful compounds will be tested and optimized for ADMET and pharmacokinetic properties and studied in rat models of Parkinson’s disease to determine their safety, efficacy and other pharmacological characteristics. The expected outcome of this project is generation of safe drug-candidates efficient against Parkinson’s disease manifestations in laboratory animals.

Wissenschaftliches Gebiet

• natural sciences › biological sciences › neurobiology
• medical and health sciences › basic medicine › medicinal chemistry
• natural sciences › biological sciences › biochemistry › biomolecules › proteins
• medical and health sciences › basic medicine › pharmacology and pharmacy › pharmacokinetics
• medical and health sciences › basic medicine › neurology › parkinson

Programm/Programme

• FP7-PEOPLE - Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)

Thema/Themen

• FP7-PEOPLE-2013-IAPP - Marie Curie Action: "Industry-Academia Partnerships and Pathways"

Aufforderung zur Vorschlagseinreichung

FP7-PEOPLE-2013-IAPP
Andere Projekte für diesen Aufruf anzeigen

Finanzierungsplan

MC-IAPP - Industry-Academia Partnerships and Pathways (IAPP)

Koordinator

HELSINGIN YLIOPISTO

Kontakt Verwaltung

Katariina Vainio-Mattila (Ms.)

• EU-Beitrag: € 440 144,10
• Adresse: YLIOPISTONKATU 3 ; 00014 Helsingin Yliopisto ; Finnland
• Region: Manner-Suomi › Helsinki-Uusimaa › Helsinki-Uusimaa
• Aktivitätstyp: Higher or Secondary Education Establishments
• Gesamtkosten: Keine Daten

Beteiligte (1)

MOLCODE AS

Estland

Kontakt Verwaltung

Vallo Paal (Mr.)

• EU-Beitrag: € 430 123,90
• Adresse: AHTRI 8 ; 10151 TALLINN
• Aktivitätstyp: Private for-profit entities (excluding Higher or Secondary Education Establishments)
• Gesamtkosten: Keine Daten